Selected Start-Ups (03/01)
Executive Summary
In Vivo summarizes the technology of several recently founded companies: Germany's Curacyte AG was formed to commercialize platforms in oncology, immunology and hematological disorders; Eliance Biotechnology Inc. has licensed a vaccine discovery platform that identifies the optimal antigens for vaccine production; Immerge Biotherapeutics will focus on the development of swine-based cells, tissues and organs for transplantation into humans; MedLynx Corp. aims to reduce hospital operating costs and reduce medical errors with its wireless, handheld medical information management system; Perlegen Sciences Inc. will read genomes from 50 individuals to discover and analyze patterns of genetic variation; Protiva Biotherapeutic Inc's gene delivery technology protects plasmid DNA from degradation as the particles are delivered through the bloodstream to their destination
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.